生物制剂相关性血管炎研究进展
Progress on biologic agents associated vasculitis
钮小玲 1黄文彦1
作者信息
- 1. 上海市儿童医院 上海交通大学医学院附属儿童医院肾脏风湿免疫科 200062
- 折叠
摘要
随着生物制剂在风湿免疫性疾病中的广泛应用,其不良反应也日益显现并受到关注.生物制剂相关性血管炎即生物制剂所引起的药物性血管炎,是其中主要且严重的一种免疫性不良反应.其病因及发病机制尚不明确,临床表现轻重不一.肿瘤坏死因子-α抑制剂最易引起血管炎,以白细胞碎裂性血管炎最为常见.生物制剂相关性血管炎的诊断相对困难,临床实践中需引起重视.停用引起血管炎的生物制剂是治疗的关键,必要时需糖皮质激素及免疫抑制剂治疗.
Abstract
While biologic agents are widely used in rheumatology practice,its side effects become apparent and are brought into focus.Biologic agents associated vasculitis are drug induced vasculitis which are induced by biologic agents.It is one of the main and severe immunological side effects by biologic agents.Its pathogenesis is unclear.And the clinical characteristic is various.Tumor necrosis factor-α inhibitors are most likely to cause vasculitis,and leukocytoclastic vasculitis is the most common one.The diagnosis of biologicagents associated vasculitis is difficult and should be paid attention in clinical practice.The biologic agents withdrawal which induced vasculitis is the critical treatment,while steroids and immune-suppressants should be given if necessary.
关键词
儿童/生物制剂/药物性血管炎/风湿免疫性疾病/不良反应Key words
Children/Biologic agents/Drug induced vasculitis/Rheumatologic and immune diseases/Side effects引用本文复制引用
出版年
2024
NETL
NSTL
万方数据